Acorah Software Products - Accounts Production 16.5.460 false true 31 March 2024 1 April 2023 false 1 April 2024 31 March 2025 31 March 2025 12127378 Mrs Dipa Pattni Mr Rajan Pattni iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12127378 2024-03-31 12127378 2025-03-31 12127378 2024-04-01 2025-03-31 12127378 frs-core:CurrentFinancialInstruments 2025-03-31 12127378 frs-core:Non-currentFinancialInstruments 2025-03-31 12127378 frs-core:FurnitureFittings 2025-03-31 12127378 frs-core:FurnitureFittings 2024-04-01 2025-03-31 12127378 frs-core:FurnitureFittings 2024-03-31 12127378 frs-core:NetGoodwill 2025-03-31 12127378 frs-core:NetGoodwill 2024-04-01 2025-03-31 12127378 frs-core:NetGoodwill 2024-03-31 12127378 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2025-03-31 12127378 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2024-04-01 2025-03-31 12127378 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2024-03-31 12127378 frs-core:ShareCapital 2025-03-31 12127378 frs-core:RetainedEarningsAccumulatedLosses 2025-03-31 12127378 frs-bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 12127378 frs-bus:FilletedAccounts 2024-04-01 2025-03-31 12127378 frs-bus:SmallEntities 2024-04-01 2025-03-31 12127378 frs-bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 12127378 frs-bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 12127378 frs-bus:Director1 2024-04-01 2025-03-31 12127378 frs-bus:Director2 2024-04-01 2025-03-31 12127378 frs-countries:EnglandWales 2024-04-01 2025-03-31 12127378 2023-03-31 12127378 2024-03-31 12127378 2023-04-01 2024-03-31 12127378 frs-core:CurrentFinancialInstruments 2024-03-31 12127378 frs-core:Non-currentFinancialInstruments 2024-03-31 12127378 frs-core:ShareCapital 2024-03-31 12127378 frs-core:RetainedEarningsAccumulatedLosses 2024-03-31
Registered number: 12127378
Elder Pharma Limited
Financial Statements
For The Year Ended 31 March 2025
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—6
Page 1
Balance Sheet
Registered number: 12127378
2025 2024
Notes £ £ £ £
FIXED ASSETS
Intangible Assets 4 704,595 923,715
Tangible Assets 5 37,296 50,504
741,891 974,219
CURRENT ASSETS
Stocks 107,323 143,901
Debtors 6 237,631 325,801
Cash at bank and in hand 221,094 294,202
566,048 763,904
Creditors: Amounts Falling Due Within One Year 7 (521,072 ) (1,017,024 )
NET CURRENT ASSETS (LIABILITIES) 44,976 (253,120 )
TOTAL ASSETS LESS CURRENT LIABILITIES 786,867 721,099
Creditors: Amounts Falling Due After More Than One Year 8 (49,522 ) (456,391 )
NET ASSETS 737,345 264,708
CAPITAL AND RESERVES
Called up share capital 2 2
Profit and Loss Account 737,343 264,706
SHAREHOLDERS' FUNDS 737,345 264,708
Page 1
Page 2
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mrs Dipa Pattni
Director
10 July 2025
The notes on pages 3 to 6 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Elder Pharma Limited is a private company, limited by shares, incorporated in England & Wales, registered number 12127378 . The registered office is 16 The Stow, Harlow, CM20 3AH.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Intangible Fixed Assets and Amortisation - Goodwill
Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to profit and loss account over its estimated economic life of 20 years.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Leasehold No depreciation
Fixtures & Fittings 25% reducing balance
2.5. Leasing and Hire Purchase Contracts
Assets obtained under finance leases are capitalised as tangible fixed assets. Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives. Assets acquired under hire purchase contracts are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the company. Obligations under such agreements are included in the creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the profit and loss account as incurred.
2.6. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
Page 3
Page 4
2.7. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
2.8. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
2.9. Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
2.10. Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
2.11. Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 8 (2024: 8)
8 8
4. Intangible Assets
Goodwill
£
Cost
As at 1 April 2024 1,022,400
Disposals (210,000 )
As at 31 March 2025 812,400
...CONTINUED
Page 4
Page 5
Amortisation
As at 1 April 2024 98,685
Provided during the period 44,995
Disposals (35,875 )
As at 31 March 2025 107,805
Net Book Value
As at 31 March 2025 704,595
As at 1 April 2024 923,715
5. Tangible Assets
Land & Property
Leasehold Fixtures & Fittings Total
£ £ £
Cost
As at 1 April 2024 9,271 73,423 82,694
Additions - 2,438 2,438
Disposals - (11,056 ) (11,056 )
As at 31 March 2025 9,271 64,805 74,076
Depreciation
As at 1 April 2024 - 32,190 32,190
Provided during the period - 9,470 9,470
Disposals - (4,880 ) (4,880 )
As at 31 March 2025 - 36,780 36,780
Net Book Value
As at 31 March 2025 9,271 28,025 37,296
As at 1 April 2024 9,271 41,233 50,504
6. Debtors
2025 2024
£ £
Due within one year
Trade debtors 142,622 197,155
Other debtors 95,009 128,646
237,631 325,801
7. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Trade creditors 208,687 284,791
Bank loans and overdrafts 26,471 26,471
Other creditors 219,380 644,862
Taxation and social security 66,534 60,900
521,072 1,017,024
Page 5
Page 6
8. Creditors: Amounts Falling Due After More Than One Year
2025 2024
£ £
Bank loans 49,522 456,391
9. Related Party Transactions
Mrs Dipa Rajan Pattni and Mr Rajan Pattni are directors of Elder Pharma Limited.
At the balance sheet date, the total amount owed by the company to the directors £166,465.10 (2023: £562,800).
During the year the company has declared a dividend of £39,000.00 (2023: £0.00).
10. Other information
Elder Pharma Limited is a private company limited by shares and incorporated in England. Its registered office is:
188 New Road
Croxley Green
Rickmansworth
England
WD3 3HD
Page 6